TScan Therapeutics Files 8-K
Ticker: TCRX · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: TSCN
TL;DR
TSCN filed an 8-K, likely with operational updates.
AI Summary
TScan Therapeutics, Inc. filed an 8-K on April 8, 2024, to report other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates TScan Therapeutics is making a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure and does not inherently present new risks without further details.
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- April 8, 2024 (date) — Date of Report
- 880 Winter Street (location) — Business Address
- Waltham (location) — City
- MA (location) — State
- 02451 (location) — ZIP Code
FAQ
What specific 'Other Events' are being reported by TScan Therapeutics in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the 'Other Events'.
When was this 8-K report filed with the SEC?
This 8-K report was filed on April 8, 2024.
What is TScan Therapeutics, Inc.'s principal executive office address?
TScan Therapeutics, Inc.'s principal executive offices are located at 880 Winter Street, Waltham, Massachusetts, 02451.
What is the Commission File Number for TScan Therapeutics, Inc.?
The Commission File Number for TScan Therapeutics, Inc. is 001-40603.
What is the Standard Industrial Classification code for TScan Therapeutics, Inc.?
The Standard Industrial Classification code for TScan Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-04-08 08:17:02
Key Financial Figures
- $0.0001 — which registered Voting Common Stock, $0.0001 par value per share TCRX The Nasdaq
Filing Documents
- d810490d8k.htm (8-K) — 25KB
- d810490dex991.htm (EX-99.1) — 13KB
- g810490g0408045731019.jpg (GRAPHIC) — 4KB
- 0001193125-24-089164.txt ( ) — 168KB
- tcrx-20240408.xsd (EX-101.SCH) — 3KB
- tcrx-20240408_lab.xml (EX-101.LAB) — 18KB
- tcrx-20240408_pre.xml (EX-101.PRE) — 11KB
- d810490d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 99.1 Press release issued by TScan Therapeutics, Inc. on April 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: April 8, 2024 By: /s/ Gavin MacBeath Gavin MacBeath Chief Executive Officer